D. Li

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

E. Liu, H. Brashear, M. Delnomdedieu, 2016, Alzheimer's Research & Therapy.

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

D. Hill, P. Scheltens, A. Gass, 2016, Alzheimer's Research & Therapy.

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

J. Pariente, R. Black, A. Ivanoiu, 2016, Alzheimer's Research & Therapy.

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

E. Liu, H. Brashear, M. Delnomdedieu, 2016, Alzheimer's Research & Therapy.